<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03530228</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_109</org_study_id>
    <nct_id>NCT03530228</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of Tegoprazan on Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Active-controlled, Single/Multiple-dose Phase 1 Clinical Trial to Evaluate Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Tegoprazan After Oral Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, active-controlled, single/multiple-dose phase 1 clinical trial to
      evaluate pharmacokinetics/pharmacodynamics and safety/tolerability of tegoprazan after oral
      administration in healthy male subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To evaluate the pharmacokinetics and pharmacodynamics of single oral dose of tegoprazan
           between dose groups in healthy H. pylori negative males.

        -  To evaluate the pharmacokinetics and pharmacodynamics of multiple oral dose of
           tegoprazan under the fed state in healthy H. pylori negative males.

        -  To evaluate the pharmacokinetics and pharmacodynamics of single oral dose of tegoprazan
           in healthy H. pylori positive males.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Cohort 1: crossover Cohort 2: parallel Cohort 3: single group</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-24h) of tegoprazan</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Area Under the Curve(0-24h) of tegoprazan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of tegoprazan</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Maximum Plasma Concentration of tegoprazan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastric pH</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Gastric pH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum gastrin concentration</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Serum gastrin concentration</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Pharmacodynamics</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Treatment A: Tegoprazan (C1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegoprazan QD, oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: Tegoprazan (C1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegoprazan QD, oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: Tegoprazan (C1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegoprazan BID, oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Tegoprazan (C2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegoprazan QD, oral administration, for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Tegoprazan (C2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegoprazan QD, oral administration, for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Esomeprazole (C2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole QD, oral administration, for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tegoprazan (C3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegoprazan QD, oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan (C1)</intervention_name>
    <description>Tegoprazan QD, oral administration. Treatment A</description>
    <arm_group_label>Treatment A: Tegoprazan (C1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan (C1)</intervention_name>
    <description>Tegoprazan QD, oral administration. Treatment B</description>
    <arm_group_label>Treatment B: Tegoprazan (C1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C: Tegoprazan (C1)</intervention_name>
    <description>Tegoprazan BID, oral administration</description>
    <arm_group_label>Treatment C: Tegoprazan (C1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan (C2)</intervention_name>
    <description>Tegoprazan QD, oral administration, for 7 days. Group 1</description>
    <arm_group_label>Group 1: Tegoprazan (C2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan (C2)</intervention_name>
    <description>Tegoprazan QD, oral administration, for 7 days. Group 2</description>
    <arm_group_label>Group 2: Tegoprazan (C2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole (C2)</intervention_name>
    <description>Esomeprazole QD, oral administration, for 7 days. Group 3</description>
    <arm_group_label>Group 3: Esomeprazole (C2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan (C3)</intervention_name>
    <description>Tegoprazan QD, oral administration</description>
    <arm_group_label>Tegoprazan (C3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males aged ≥ 19 years and ≤ 50 years

          -  Body weight of ≥ 55.0 kg and ≤ 90.0 kg, with body mass index (BMI) of ≥ 18.0 kg/m2 and
             ≤ 27.0 kg/m2 at the time of screening

        Exclusion Criteria:

          -  Presence or history of clinically significant diseases

          -  Presence or history of gastrointestinal disorder (gastric ulcer, GERD, - Crohn's
             disease, etc.)

          -  Hypersensitivity to drugs containing study drug or proton pump inhibitor and other
             drugs (aspirin, antibiotics, etc.) or history of clinically significant
             hypersensitivity

          -  Serologic test positive

          -  Abnormal obstacle to insertion and maintenance of pH meter catheter

          -  History of drug abuse

          -  Excessive caffeine intake or persistent alcohol intake

          -  Not use of a medically acceptable method of contraception
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>In Jin Jang, MD, PhD</last_name>
    <phone>82-2-2072-1666</phone>
    <email>ijjang@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mu Seong Ban, MD</last_name>
    <phone>82-2-2072-1666</phone>
    <email>ban2699@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In Jin Jang, MD, PhD</last_name>
      <phone>82-2-2072-1666</phone>
      <email>ijjang@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Mu Seong Ban, MD</last_name>
      <phone>82-2-2072-1666</phone>
      <email>ban2699@snu.ac.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>May 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2018</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

